Search for: "In Re: Pharmaceutical Case, et al"
Results 1 - 20
of 266
Sort by Relevance
|
Sort by Date
9 May 2024, 11:30 am
One of the “constitutional failures” he uncovers is the Court’s failure to find a right to drug use based on the same substantive due process analysis that determined cases like Roe v. [read post]
22 Apr 2024, 5:00 am
—, 144 S.Ct. 756 (March 15, 2024), considered with a companion case O’Connor-Radcliffe v. [read post]
3 Apr 2024, 9:05 pm
Tex. 2001). [7] See Torben Andersen et al., A Descriptive Study of High-Frequency Trade and Quote Options Data, 19 J. [read post]
28 Feb 2024, 2:00 pm
” (Green et al., Reference Guide on Epidemiology, in Reference Manual on Scientific Evidence (3d ed. 2011) 549, 552, 598.) [read post]
23 Jan 2024, 11:32 am
The cases are cropping up. [read post]
9 Jan 2024, 7:06 am
Salix Pharmaceuticals et al. v. [read post]
19 Nov 2023, 2:31 pm
Chubin et al. at 10, Daubert v. [read post]
19 Dec 2022, 2:31 am
NPR, Al Jazeera and CNN cover the claim. [read post]
29 Aug 2022, 9:05 pm
Other criminal cases in these areas r [read post]
24 Aug 2022, 4:00 am
Each Wednesday we tell you which three English-language cases and French-language cases have been the most viewed* on CanLII and we give you a small sense of what the cases are about. [read post]
19 Jul 2022, 2:59 pm
Our analysis shows that about two-thirds of these cases are dismissed in full. [read post]
19 Jun 2022, 5:05 pm
In a seminal discrimination case, Casteneda v. [read post]
17 Jun 2022, 2:09 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), legal scholars, judges, and lawyers have struggled with the structure and validity of expert opinion on specific causation. [read post]
14 Mar 2022, 11:23 am
Inc. et al. v. [read post]
5 Jan 2022, 7:16 am
The case, In Re Valsartan, Losartan, and Irbesartan Products Liability Litigation (US DC NJ) MDL No. 2875 (RBK)is a products liability case that concerns the sale in the U.S. of generic, prescription Valsartan pharmaceuticals, found by the Food and Drug Administration [“FDA”] to contain cancer‐causing contaminants. [read post]
4 Oct 2021, 1:52 pm
Post-AIA (Point Estimate) We thank LaTia Brand of Harrity Analytics and the Stanford NPE Database, described in Shawn Miller et al., Who’s Suing Us? [read post]
4 Oct 2021, 1:52 pm
Post-AIA (Point Estimate) We thank LaTia Brand of Harrity Analytics and the Stanford NPE Database, described in Shawn Miller et al., Who’s Suing Us? [read post]
26 Sep 2021, 7:28 pm
Chou, et al., No. 2019-0816-SG opinion issued (Del. [read post]
13 Jul 2021, 10:58 am
THE PROPOSED TRIPS WAIVER.. 6 THE CASE FOR AND AGAINST A COMPREHENSIVE TRIPS WAIVER.. 8 REVIEWING ALTERNATIVE OR COMPLEMENTARY PROPOSALS FOR ACHIEVING COVID-19 GLOBAL HERD IMMUNITY.. 12 CONCLUSION: A MULTILATERAL SOLUTION FOR ADDRESSING EMERGING CHALLENGES DURING THE COVID-19 PANDEMIC.. 14 INTRODUCTION This paper is motivated by the tension between international intellectual property (IP) protection and countries’ abilities to respond to… [read post]
13 May 2021, 2:24 pm
Thus, it is not uncommon for there to be several dozen statutes of repose in securities fraud cases involving long-running frauds. [read post]
